Skip to content
Tokyo Brief東 京 ブ リ ー フJapan's day, wrapped and delivered by morning.
Company
Companies

Rohto Pharmaceutical

ロート製薬

4527 · TSE · Pharmaceutical · 2 articles

Financials Consolidated

Revenue¥344bn+11.4% year on yearConsolidated · FY3/26

Ordinary profit¥48.0bn+20.8% year on yearConsolidated · FY3/26

Net profit¥34.2bn+11.0% year on yearConsolidated · FY3/26

Dividend per share¥46.00FY3/26

Performance over time

Revenue
¥200bnFY3/22
¥239bnFY3/23
¥271bnFY3/24
¥309bnFY3/25
¥344bnFY3/26
Ordinary profit
¥28.8bnFY3/22
¥35.6bnFY3/23
¥42.4bnFY3/24
¥39.7bnFY3/25
¥48.0bnFY3/26
Net profit (attributable)
¥21.1bnFY3/22
¥26.4bnFY3/23
¥30.9bnFY3/24
¥30.8bnFY3/25
¥34.2bnFY3/26
Op. cash flow
¥27.3bnFY3/22
¥30.9bnFY3/23
¥34.2bnFY3/24
¥36.9bnFY3/25
¥47.8bnFY3/26

People & pay

Employees, whole group9,292 peopleFY3/26

Employees, parent company (non-consolidated)1,786 peopleFY3/26

Average salary¥8.51mFY3/26

Average salary is for the parent company's own employees (non-consolidated), as Japanese annual reports disclose it.

Five-year history
Five-year history
Fiscal yearRevenueOrdinary profitNet profit (attributable)EPSDividendTotal assetsNet assetsOp. cash flow
FY3/26¥344bn+11.4% year on year¥48.0bn¥34.2bn¥151.56¥46.00¥486bn¥320bn¥47.8bn
FY3/25¥309bn+14.0% year on year¥39.7bn¥30.8bn¥135.38¥36.00¥437bn¥281bn¥36.9bn
FY3/24¥271bn+13.5% year on year¥42.4bn¥30.9bn¥135.61¥27.00¥346bn¥247bn¥34.2bn
FY3/23¥239bn+19.5% year on year¥35.6bn¥26.4bn¥115.62¥32.00¥310bn¥215bn¥30.9bn
FY3/22¥200bn¥28.8bn¥21.1bn¥92.61earlier report differs¥36.00¥275bn¥184bn¥27.3bn

Earlier report differs: an earlier annual report stated the same period's figure more than 5% differently; the latest report's figure is shown.

Per-share figures are as each report states them: a share split is restated only for the year before it, and dividends are as paid.

Figures from annual report S100YE5N · Japan GAAP. Each figure's years come from one report's five-year summary.

Latest coverage

TSE:4527

  1. Keio Hospital to start physician-led trial of Cyfuse's bioprinted knee implant

    Cyfuse Biomedical said Keio University Hospital will run a physician-initiated trial of its bioprinted KCF-BC1 knee implant, with the release citing rabbit and minipig data and the earnings effect for the year to December 2026 still under review.

  2. Rohto lifts its 2030 sales target to ¥444bn but trims the margin goal

    Rohto Pharmaceutical lifted its 2030 sales target to ¥444.0bn from ¥415.0bn while lowering the margin goal to 12.8% from 13%, and set 2031 targets including a 40% dividend payout ratio.

Buybacks

Authorised and executed under the company’s current programmes.

1 programme · data through

The line marks how much of the buying window has passed; a bar beyond it is buying ahead of pace.

Buybacks
ResolutionProgress by companyFiling
Runs to 31 Dec 2026100% of yen limit used¥3bn / ¥3bn · 1.04m / 1.5m shares78% of the buying window to 31 Dec 2026 has passedFiled  — filing S100ZDAM

AGM votes

This season’s shareholder voting results.

1 meeting · data through

AGM votes
ProposalApprovalResultFiling
Election of 14 directors
Original (Japanese)取締役14名選任の件
· 山田 邦雄
89.42%Votes cast: 89.68%ApprovedFiled  — filing S100YLZB
Election of 14 directors
Original (Japanese)取締役14名選任の件
· 瀬木 英俊
91.71%Votes cast: 91.98%ApprovedFiled  — filing S100YLZB
Election of 14 directors
Original (Japanese)取締役14名選任の件
· 斉藤 雅也
91.48%Votes cast: 91.74%ApprovedFiled  — filing S100YLZB
Election of 14 directors
Original (Japanese)取締役14名選任の件
· 國﨑 伸一
96.04%Votes cast: 96.31%ApprovedFiled  — filing S100YLZB
Election of 14 directors
Original (Japanese)取締役14名選任の件
· 藤本 陽子
98.51%Votes cast: 98.79%ApprovedFiled  — filing S100YLZB
Show 17 more meetings (22 total)
AGM votes
ProposalApprovalResultFiling
Election of 14 directors
Original (Japanese)取締役14名選任の件
· 河﨑 保徳
96.07%Votes cast: 96.34%ApprovedFiled  — filing S100YLZB
Election of 14 directors
Original (Japanese)取締役14名選任の件
· 山中 雅恵
96.08%Votes cast: 96.36%ApprovedFiled  — filing S100YLZB
Election of 14 directors
Original (Japanese)取締役14名選任の件
· 本間 陽一
96.09%Votes cast: 96.37%ApprovedFiled  — filing S100YLZB
Election of 14 directors
Original (Japanese)取締役14名選任の件
· 末延 則子
98.50%Votes cast: 98.78%ApprovedFiled  — filing S100YLZB
Election of 14 directors
Original (Japanese)取締役14名選任の件
· 入山 章栄
96.46%Votes cast: 96.74%ApprovedFiled  — filing S100YLZB
Election of 14 directors
Original (Japanese)取締役14名選任の件
· 米良 はるか
95.84%Votes cast: 96.11%ApprovedFiled  — filing S100YLZB
Election of 14 directors
Original (Japanese)取締役14名選任の件
· 林 依利子
99.22%Votes cast: 99.51%ApprovedFiled  — filing S100YLZB
Election of 14 directors
Original (Japanese)取締役14名選任の件
· 片田江 舞子
99.20%Votes cast: 99.49%ApprovedFiled  — filing S100YLZB
Election of 14 directors
Original (Japanese)取締役14名選任の件
· 岩田 彰一郎
98.04%Votes cast: 98.32%ApprovedFiled  — filing S100YLZB
Dismissal of 1 director(s)Machine translated
Original (Japanese)取締役1名解任の件
11.20%†Votes cast: 11.20%† Percentage of votes cast; company did not state a ratio.RejectedFiled  — filing S100YLZB
Amendment of the articles of incorporation regarding the establishment of a Strategy Review CommitteeMachine translated
Original (Japanese)戦略検討委員会の設置に関する定款変更の件
8.98%†Votes cast: 8.98%† Percentage of votes cast; company did not state a ratio.RejectedFiled  — filing S100YLZB
Amendment of the Articles of Incorporation regarding the decision-making body for dividends of surplus, etc.Machine translated
Original (Japanese)剰余金の配当等の決定機関に関する定款変更の件
48.17%†Votes cast: 48.17%† Percentage of votes cast; company did not state a ratio.RejectedFiled  — filing S100YLZB
Matter of repurchase of the company's own sharesMachine translated
Original (Japanese)自己株式取得の件
11.14%†Votes cast: 11.14%† Percentage of votes cast; company did not state a ratio.RejectedFiled  — filing S100YLZB
Approval of the remuneration amount under the restricted stock compensation systemMachine translated
Original (Japanese)譲渡制限付株式報酬制度に関する報酬額承認の件
17.40%†Votes cast: 17.40%† Percentage of votes cast; company did not state a ratio.RejectedFiled  — filing S100YLZB
Amendment of the articles of incorporation regarding the composition of outside directorsMachine translated
Original (Japanese)社外取締役の構成に関する定款変更の件
15.01%†Votes cast: 15.01%† Percentage of votes cast; company did not state a ratio.RejectedFiled  — filing S100YLZB
Amendment of the Articles of Incorporation regarding measures toward realizing management that takes into account the cost of capital and share priceMachine translated
Original (Japanese)資本コストや株価を意識した経営の実現に向けた対応に関する定款変更の件
13.56%†Votes cast: 13.56%† Percentage of votes cast; company did not state a ratio.RejectedFiled  — filing S100YLZB
Matter regarding amendment of the Articles of Incorporation concerning the record date of the annual general meeting of shareholdersMachine translated
Original (Japanese)定時株主総会の基準日に関する定款変更の件
9.45%†Votes cast: 9.45%† Percentage of votes cast; company did not state a ratio.RejectedFiled  — filing S100YLZB

Approval is the ratio the company states (usually of the voting rights of shareholders present); votes cast are for ÷ (for + against + abstain).

† Percentage of votes cast; company did not state a ratio.

† Company-stated ratio differs from tallied votes.

Cross-holdings

Strategic shareholdings and sales, by fiscal year.

6 fiscal years · data through

Balance-sheet value
¥9.5bnFY3/22
¥12.8bnFY3/23
¥15.2bnFY3/24
¥12.5bnFY3/25
¥15.5bnFY3/26

Balance-sheet value is the reporting company's own listed holdings (its largest holding subsidiary's where marked), carried at market value; the percentage divides it by consolidated net assets in the same annual report.

Cross-holdings
Fiscal year endHoldings (issuers)Balance-sheet value% of consolidated net assetsIssues cutSale proceedsFiling
31 Mar 202625¥15.5bn4.85%——Filed  — filing S100YE5N
Show 5 more fiscal years (6 total)
Cross-holdings
Fiscal year endHoldings (issuers)Balance-sheet value% of consolidated net assetsIssues cutSale proceedsFiling
31 Mar 202524¥12.5bn4.60%——Filed  — filing S100WCHQ
31 Mar 202426¥15.2bn6.15%——Filed  — filing S100TX7A
31 Mar 202324¥12.8bn5.97%——Filed  — filing S100R8E4
31 Mar 202220¥9.55bn5.19%1¥500mFiled  — filing S100OFES
31 Mar 202121¥11.1bn7.07%2¥150mFiled  — filing S100LOGZ

Fund positioning

Current holdings disclosed by tracked funds.

25 funds · data through

Held by 25 tracked funds; largest weight 1.40%. Holdings as of 31 Jul 2026–18 Nov 2026.

Show 15 more funds (25 total)